|
Today's Headlines
Patients with cancer who use statins regularly may have a lower risk of cancer-related mortality, according to a study published November 8 in the New England Journal of Medicine. » Full article
|
|
The direct renin inhibitor aliskiren, added to standard therapy with renin-angiotensin system blockade, in patients with type 2 diabetes who are at risk for cardiovascular and renal adverse events was not useful at lowering these events and may even be harmful, according to an online study published in the New England Journal of Medicine. » Full article
|
|
An automated online self-management program may help employees with prehypertension or hypertension achieve adequate blood pressure control, according to a study published in the October issue of American Heart Journal. » Full article
|
|
Sleep restriction may contribute to poor health, including an increased risk for insulin resistance, type 2 diabetes, and obesity. In addition, fewer hours of sleep can adversely affect molecular metabolic pathways in peripheral human adipocytes, according to a clinical study published in the October issue of Annals of Internal Medicine. » Full article
|
|
CONTINUING EDUCATION
Welcome to the third activity of our CPE series: Medication Therapy Management (MTM) in Patients with Diabetes, which has been designed for pharmacists who take care of patients with diabetes. You can earn up to 14 credits from September 2012-March 2013 with 7 monthly knowledge-based activities. The November activity will cover oral antidiabetes agents and noninsulin injectables for diabetes care.
To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to login.
Coming soon - All users will be required to provide their NABP e-Profile ID when logging into the Drug Topics' FREE CPE. This new process requires all pharmacists and pharmacy technicians to provide their NABP e-Profile ID prior to accessing the system. If you have not done so, you can obtain your NABP e-Profile ID now at www.MyCPEmonitor.net This profile will enable you to have one login for all the NABP programs and services you will need throughout your career.
|
|
EDITOR'S PICK
Rheumatoid arthritis (RA) is associated with significant disability and socioeconomic costs because it is estimated to affect up to 1% of the adult population in the United States. Greater understanding of the process of RA has led to new treatments emerging for the disease that target its pathogenesis instead of its symptoms. This review discusses the current standards of care and details the most recent data being collected on new pharmacologic agents for the treatment of RA. » Full article
|
Survey
a) Further broaden the gap between copay dollar value between preferred and non-preferred brand drug tiers.
b) Demand increase formulary rebates requested from manufacturers of preferred products.
c) Implement more aggressive utilization management (PA, Step, Therapeutic Interchange, etc.) to specifically target these products.
d) Enhanced employment of a closed-formulary benefit design.
e) No action, as I dont believe this couponing will have significant effects.
Respond here and see what your colleagues think too.Want to see the results of our last survey. Click here.
|
|
|
Like
Tweet
